CardiASC, 100 mg 30 pcs

NSAID, antiaggregant. The main mechanism of action of the drug CardIASC is irreversible inactivation of cyclooxygenase enzyme (COX-1), as a result of which the synthesis of thromboxane A2 is blocked and platelet aggregation is suppressed. CardIASC also has anti-inflammatory, antipyretic and analgesic effects.

Pharmacokinetics

Assimilation

.

After oral administration, acetylsalicylic acid is absorbed in the upper small intestine. Cmax in plasma is reached 3 hours after oral administration.

Metabolism

Acetylsalicylic acid is partially metabolized in the liver to form less active metabolites.

Elimation

Extracted by the kidneys both unchanged and as metabolites. T1/2 for acetylsalicylic acid is 15 minutes, for metabolites – about 3 hours.

Indications

– Prevention of acute myocardial infarction in the presence of risk factors (including diabetes.

Prevention of acute myocardial infarction in the presence of risk factors (including diabetes, hyperlipidemia, hypertension, obesity, smoking, old age) and recurrent myocardial infarction;

Instable angina;

Prevention of stroke (including

– prevention of transient cerebral circulatory disorders;

– prevention of thromboembolism after operations and invasive vascular interventions (including

– prevention of deep vein thrombosis and thromboembolism of the pulmonary artery and its branches (including in case of prolonged immobilization as a result of extensive surgical intervention).

Active ingredient

Composition

Tablets

Active ingredient:

acetylsalicylic acid;

Associates:

Corn starch,

lactose,

microcrystalline cellulose,

Plasdon K-90,

calcium stearate,

tween-80,

collicut MAE 100P,

Plasdon S-630,

propylene glycol,

Talc,

Castor oil,

Titanium dioxide.

How to take, the dosage

CardIASC® should be taken orally before meals with plenty of fluid.
CardIASC® is intended for long-term use. The duration of therapy is determined by the attending physician.
– Prophylaxis in case of suspected acute myocardial infarction
100-200 mg/day or 300 mg every other day (the first tablet should be chewed for faster absorption).
– Prevention of first-time acute myocardial infarction in the presence of risk factors
100 mg daily or 300 mg every other day.
– Prevention of recurrent myocardial infarction. Unstable angina pectoris. Prevention of stroke and transient cerebral circulation disorder. Prevention of thromboembolic complications after surgical operations or invasive investigations
100-300 mg daily
– Prevention of deep vein thrombosis and thromboembolism of the pulmonary artery and its branches
100-200 mg daily or 300 mg every other day.

Interaction

When used concomitantly ASA increases the effect of the following drugs:

– metotrescate by reducing renal clearance and displacing it from protein binding;

– heparin and indirect anticoagulants due to the disturbance of platelet function and displacement of indirect anticoagulants from protein binding;

– thrombotic and antiplatelet drugs (ticlopidine);

–

– antidiabetic drugs (insulin and sulfonylurea derivatives) due to hypoglycemic properties of ASA itself at high doses and displacing sulfonylurea derivatives from protein binding;

– valproic acid due to its displacement from protein binding.

Additive effect is observed when concomitant administration of ASA with alcohol.

ASK attenuates the effect of uricosuric drugs (benzbromaron) due to competitive tubular elimination of uric acid.

By enhancing the elimination of salicylates, systemic glucocorticosteroids (GCS) attenuate their effects.

Special Instructions

The drug CardiASC should be used after prescribing by a physician.

ASK can cause bronchospasm, and can also cause bronchial asthma attacks and other hypersensitivity reactions.

The risk factors include a history of bronchial asthma, hay fever, nasal polyposis, chronic respiratory disease, and allergic reactions to other drugs (e.g., skin reactions, itching, urticaria).

ASK can cause bleeding of varying severity during and after surgical interventions.

Combination of ASA with anticoagulants, thrombolytics and antiplatelet agents is accompanied by an increased risk of bleeding.

ASK in low doses may provoke development of gout in predisposed individuals (who have reduced excretion of uric acid).

Combining Asc and methotrexate is accompanied by an increased incidence of hematopoietic side effects.

High doses of Asc have a hypoglycemic effect, which should be kept in mind when prescribing it to patients with diabetes mellitus who are receiving hypoglycemic drugs.
When prescribing GCS and salicylates concomitantly it should be remembered that during treatment the level of salicylates in blood is decreased and after withdrawal of GCS an overdose of salicylates is possible.

The combination of ASA with ibuprofen is not recommended because the latter worsens the beneficial effects of ASA on longevity.

Exceeding the dose of ASA is associated with the risk of gastrointestinal bleeding.

Overdose is especially dangerous in elderly patients.

When ASA is combined with alcohol, there is an increased risk of gastrointestinal mucosal damage and prolonged bleeding time.

Contraindications

– gastrointestinal erosive and ulcerative lesions;

– gastrointestinal bleeding;

– bronchial asthma induced by taking salicylates and NSAIDs;

– “aspirin triad” (Fernand-Vidal triad: combination of bronchial asthma, recurrent polyposis of the nose and sinuses, and intolerance of acetylsalicylic acid);

– hemorrhagic diathesis;

– combined use with methotrexate at a dose of 15 mg per week or more;

– hepatic impairment;

– renal impairment;

– first and third trimester of pregnancy;

– lactation (breastfeeding);

– age under 18 years;

– hypersensitivity to acetylsalicylic acid and other NSAIDs.

With cautious. CardiASC is indicated for gout, hyperuricaemia, and patients with a history of gastrointestinal ulcers or gastrointestinal bleeding, bronchial asthma, and chronic respiratory disease, hay fever, nasal polyposis, allergic reactions to medicinal products, when concomitant use with methotrexate in doses less than 15 mg weekly, in vitamin K and glucose-6-phosphate dehydrogenase deficiency.

Side effects

Allergic reactions: urticaria, Quincke’s edema.

Gastrointestinal tract: nausea, heartburn, vomiting, abdominal pain, gastric and duodenal ulcers, including perforative, gastrointestinal bleeding, increased activity of “liver” enzymes.

Respiratory system: bronchospasm.

Immune system: anaphylactic reactions.

Blood system disorders: anemia (rare), increased bleeding.

Central nervous system: dizziness, tinnitus.

Overdose

Symptoms of cardiac overdose of moderate severity:
Nausea, vomiting, tinnitus, hearing impairment, dizziness, confusion.

Treatment:

Dose reduction of the drug.

Serious overdose symptoms of CardiASC:

Fever, hyperventilation, ketoacidosis, respiratory alkalosis, coma, cardiovascular and respiratory failure, marked hypoglycemia.
Treatment: immediate admission to specialized departments for emergency therapy – gastric lavage, determination of acid-base status, alkaline and forced alkaline diuresis, hemodialysis, solutions administration, activated carbon, symptomatic therapy. When performing alkaline diuresis, it is necessary to achieve pH values between 7.5 and 8. Forced alkaline diuresis should be performed when plasma concentration of salicylates is over 500 mg/l (3.6 mmol/l) in adults and 300 mg/l (2.2 mmol/l) in children.

Similarities